Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.A241385
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Inolimomab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Inolimomab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inolimomab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Inolimomab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Inolimomab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Inolimomab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Inolimomab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inolimomab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Inolimomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inolimomab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Inolimomab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inolimomab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Inolimomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Inolimomab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Inolimomab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Inolimomab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Inolimomab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Canakinumab is combined with Inolimomab. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Tocilizumab is combined with Inolimomab. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Inolimomab. |
| Golimumab | The risk or severity of adverse effects can be increased when Golimumab is combined with Inolimomab. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Inolimomab. |
| Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Inolimomab. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Inolimomab. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Inolimomab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Secukinumab is combined with Inolimomab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Vedolizumab is combined with Inolimomab. |
| Siltuximab | The risk or severity of adverse effects can be increased when Siltuximab is combined with Inolimomab. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Blinatumomab is combined with Inolimomab. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Dinutuximab is combined with Inolimomab. |
| Antilymphocyte immunoglobulin (horse) | The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Inolimomab. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Ixekizumab is combined with Inolimomab. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Ravulizumab is combined with Inolimomab. |
| Sarilumab | The risk or severity of adverse effects can be increased when Sarilumab is combined with Inolimomab. |
| Brodalumab | The risk or severity of adverse effects can be increased when Brodalumab is combined with Inolimomab. |
| Sirukumab | The risk or severity of adverse effects can be increased when Sirukumab is combined with Inolimomab. |
| Guselkumab | The risk or severity of adverse effects can be increased when Guselkumab is combined with Inolimomab. |
| Emapalumab | The risk or severity of adverse effects can be increased when Emapalumab is combined with Inolimomab. |
| Risankizumab | The risk or severity of adverse effects can be increased when Risankizumab is combined with Inolimomab. |
| Rozanolixizumab | The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Inolimomab. |
| Bleselumab | The risk or severity of adverse effects can be increased when Bleselumab is combined with Inolimomab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Inolimomab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Inolimomab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Inolimomab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Inolimomab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Inolimomab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Inolimomab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Inolimomab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Inolimomab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Inolimomab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Inolimomab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Inolimomab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Inolimomab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Inolimomab. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Inolimomab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Inolimomab. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Inolimomab. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Inolimomab. |
| Cladribine | Inolimomab may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Inolimomab. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Inolimomab. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Inolimomab. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Inolimomab. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Inolimomab. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Inolimomab. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Inolimomab. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Inolimomab. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Inolimomab. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Inolimomab. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Inolimomab. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Inolimomab. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Inolimomab. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Inolimomab. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Inolimomab. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Inolimomab. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Inolimomab. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Inolimomab. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Inolimomab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Inolimomab. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Inolimomab. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Inolimomab. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Inolimomab. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Inolimomab. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Inolimomab. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Inolimomab. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Inolimomab. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Inolimomab. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Inolimomab. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Inolimomab. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Inolimomab. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Inolimomab. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Inolimomab. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Inolimomab. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Inolimomab. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Inolimomab. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Inolimomab. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Inolimomab. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Inolimomab. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Inolimomab. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Inolimomab. |